key: cord-0036157-utei6vqd authors: Blennow, Ola; Ljungman, Per title: Infections in Hematology Patients date: 2018-11-16 journal: Concise Guide to Hematology DOI: 10.1007/978-3-319-97873-4_38 sha: 0c70587aba7fdbbf833d9281eb4efe044044a2c8 doc_id: 36157 cord_uid: utei6vqd Infections are major causes of morbidity and mortality in hematology patients especially those having undergone allogeneic hematopoietic stem cell transplantation. The management relies on early diagnosis and rapid introduction of appropriate antimicrobial drugs frequently before the infectious agent has been identified. The use of broad-spectrum antibacterial drugs has reduced the mortality in febrile neutropenia. However, the increase of multiresistant strains has in several countries become a major threat, and the development of new antibacterial drugs is urgently needed. Infection control strategies are also very important to limit the spread of multiresistant bacteria. Early diagnosis with imaging and tests for antigen or DNA is important for the management of fungal infections. High-risk patients should also receive prophylaxis. Viral infections are important causes of severe disease in patients having undergone allogeneic stem cell transplantation but do occur also in non-transplanted patients. Early diagnosis usually with tests for viral nucleic acids is the key for appropriate management. Prevention and treatment with antiviral drugs are available for some viruses especially herpesviruses. In hematology patients, the immunosuppression caused by the hematologic disease and its treatment usually predicts both the severity and type of infections. Neutropenia predisposes to severe bacterial infections and, if prolonged, for fungal infections, while an impaired T-cell function increases the risk for fungal and viral infections. Besides knowledge about the patients' immune status, the local resistance pattern, such as the frequencies of extended spectrum betalactamase (ESBL)-producing Enterobacteriaceae and methillicin-resistant Staphylococcus aureus (MRSA), is important when deciding on empirical antimicrobial therapies. An important diagnostic principle in immunosuppressed patients is to "go for the bug" at the place of infection using invasive procedures, most often bronchoalveolar lavage (BAL) and biopsies. Prevention of infection in hematology patients consists of antimicrobial prophylaxis, prevention of exposure to infectious agents, and immune prophylaxis (vaccination; immune globulin). Most studies of antibacterial prophylaxis have been performed with fluoroquinolones. Although the risk for neutropenic fever can be reduced, the effects on outcome have been variable, and its use is controversial due to the increased rates of resistance. If antibacterial prophylaxis is to be used, it should be reserved only to high-risk patients. Antifungal and antiviral prophylaxis regimens are discussed in sections dealing with the specific pathogens further on in this chapter. Other preventive measures are described in Table 38 .1. A. Epidemiology: 1. Neutropenic fever is usually defined as a single temperature measurement of ≥38.3 °C (101 °F) or a temperature of ≥38.0 °C (100.4 °F) sustained over a 1-h period in a patient with ANC <500 cells/μL. 2. It is very common in patients with hematologic malignancies and occurs in more than 80% of patients with chemotherapy-associated neutropenia. 3 . In approximately 50% of episodes, no diagnosis can be established (i.e., fever of unknown origin, FUO), whereas clinically documented infections and microbiological documented infections are diagnosed in around 25% of episodes each. 4. Bloodstream infections constitute the vast majority of microbiological documented infections. The epidemiology of bloodstream infections differs between centers, but generally there is a slight dominance of Gram-negative enteric bacteria (such as E. coli, K. pneumoniae, P. aeruginosa) over Grampositive pathogens (such as coagulase-negative staphylococci, viridans streptococci, E. faecium). Antimicrobial resistance is rapidly increasing among both Gram-negative and Gram-positive isolates, most importantly extended ESBL production in Enterobacteriaceae. 5. The all-over mortality is low, around 5%, due to low mortality in patients with FUO. In patients with documented infections, the reported mortality rates are considerably higher: around 20% in patients with lung infiltrates, 35% in severe sepsis, and 50% in patients with septic shock [1] . B. Diagnostics: 1. A careful clinical examination should be performed daily to identify possible infection focuses and detect clinical deterioration. Focuses that are easily overlooked include dental infections and perianal infections. 2. Blood cultures should be taken through the central catheter and peripherally simultaneously, making it possible to identify catheter-related bloodstream infections (see section "CRBSI"). The total blood volume should be at least 40 ml (i.e., four bottles) to reach an acceptable sensitivity. 3. Other cultures depend on the clinical signs of infection. Possible specimens include sputum, urine, skin, and stool samples (for Clostridium difficile). 4 . PCR for respiratory viruses should be performed in severely immunocompromised patients with respiratory symptoms especially in influenza season. PCR for other viruses is usually not part of the initial workup. 5. In patients with respiratory symptoms, a thoracic CT scan should be performed. Chest X-ray is not meaningful in neutropenic patient because of low sensitivity and specificity (see also section "Pneumonia"). 6. BAL should be performed if the CT scan shows lung infiltrates ( has not been shown to decrease mortality and duration of fever and should be avoided. 5. If the patient deteriorates, the antimicrobial therapy must be changed to include an even broader coverage. A carbapenem (meropenem or imipenem/ cilastatin) should be prescribed if not already given. Empirical antifungal therapy should be initiated (see section "Empirical Antifungal Therapy"), and addition of amikacin and/or vancomycin considered. A. Epidemiology: (a) Respiratory symptoms and/or a new lung infiltrate are frequent in patients with hematologic diseases. In patients receiving treatment for acute leukemia, up to 30% may be affected with an associated mortality of over 20% [6] . (b) The etiology often depends on the underlying immunosuppression ( A. Epidemiology: 1. Different definitions of CRBSI exist, but common and clinical useful definitions are (1) growth in central blood culture at least 2 h before peripheral blood culture or (2) A. Typhlitis is a potentially serious complication in neutropenic patients characterized by fever, abdominal pain, and thickening of the cecum and adjacent ileum [9] . B. The pathogenesis involves intestinal damage associated with neutropenia and mucositis, followed by microbial invasion with inflammation and ulceration. C. The reported incidence varies, depending on the definitions and intensity of chemotherapy, from 5% in all patients with hematologic malignancies up to 28% in patients with AML [9] . D. Ultrasound or CT scan showing bowel wall thickening in a neutropenic patient with fever and abdominal pain is diagnostic. E. Blood cultures and Clostridium difficile assays should be performed, and antimicrobial treatment covering Gramnegatives, including Pseudomonas aeruginosa, and anaerobes should be instituted promptly. Suitable options include monotherapy with meropenem, imipenem/cilastatin, or piperacillin/tazobactam or a combination of cefepime and metronidazole. F. Translocation of Candida species may occur, and empirical treatment/prophylaxis with a candida-active agent, such as fluconazole or an echinocandin, should be considered. G. Bowel rest and G-CSF to shorten the duration of neutropenia may be considered, but evidence for effect are lacking. H. Surgery should be avoided unless absolute necessary (perforation or massive bleeding) [9] . A. Empirical and preemptive antifungal therapy: 1. Epidemiology: (a) Prolonged neutropenic fever despite broadspectrum antibiotic therapy is common, and empirical antifungal therapy based on this indication only will lead to administration of antifungals to around one third of neutropenic patients. However, the majority of these patients do not have an invasive fungal disease (IFD), and indiscriminate empirical antifungal therapy will thus expose patients to unnecessary and potentially harmful drugs. (b) The incidence of IFD is approximately 5-10% in high-risk patients receiving candida-active prophylaxis, such as AML/MDS patients receiving remission-intended chemotherapy. In patients receiving mold-active prophylaxis, usually posaconazole or voriconazole, the reported frequency of breakthrough IFD is considerably lower, between 0.5% and 1.5% [10] . 1. In the empirical approach, antifungal treatment is initiated after 72-96 h of neutropenic fever despite broad-spectrum antibiotics, even if there are no other signs or findings suggestive of IFD. As discussed above this approach will expose many patients to unnecessary and potentially harmful treatment and is not recommended. 2. In the preemptive approach, patients are screened in blood/plasma two to three times per week with one or more biomarkers, most often GM. If a biomarker becomes positive, a thoracic CT scan is performed, and if infil-trates are present, BAL are performed, and empirical antifungal therapy started. In patients with negative CT scans, screening with biomarkers continues, and no antifungals are started. If a biomarker becomes positive again, the procedure with a thoracic CT scan is repeated. Studies have shown that this approach significantly reduces the use of antifungals without reducing overall survival, although the frequency of diagnosed IFD was slightly higher than in the empirical arm [13] . 3. In the diagnostic approach, biomarkers and thoracic CT scans are performed in high-risk patients with neutropenic fever for more than 3-5 days despite broad-spectrum antibiotics. Such as T-cell-directed antibodies (thymoglobulin, alemtuzumab) and/or prolonged treatment with high-dose corticosteroids c Only if low incidence of mold infections. May also be given as part of an integrated care strategy together with a mold-directed diagnostic approach (includes weekly screening with biomarkers during periods of high risk) (c) A thoracic CT scan should always be performed. Typical findings include nodules, consolidative lesions, wedge-shaped infarcts, and the halo sign: a nodule >1 cm in diameter surrounded by a groundglass opacity reflecting hemorrhage [16, 18] . (d) Diagnostic BAL should always be performed unless contraindicated (Table 38 .4), and sputum should be sent for microscopy and culture [12, 16] . (e) Since the diagnostic yield of microscopy and culture is limited, other tests have been developed. All the available tests have weaknesses and best results have been reported when combining two (or more) tests [11, 19] . 1. Galactomannan (GM) antigen test is the most used. GM constitutes part of the Aspergillus fungal wall and can be detected in serum and BAL (and in CSF) with a commercial test that is FDA approved. In neutropenic hematology patients, the sensitivity is around 70% when tested in serum and higher in BAL. In patients receiving mold-active treatment, the sensitivity is significantly reduced. 2. Aspergillus-specific lateral-flow device is an antigen test with a performance similar to GM with the advantage of providing a test result within minutes but is not as well documented [19] . Candida Infections") has a sensitivity similar or just below the one of GM but poor specificity due to high rate of false-positive results and because a true-positive test is not specific for Survival in neutropenic patients with severe sepsis or septic shock Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th The challenge of antibiotic resistance in haematology patients Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies Management of anorectal and intra-abdominal infections in the neutropenic cancer patient Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNAmicroarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR Initiative Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Isavuconazole treatment for mucormycosis: a single-arm open-label trial and casecontrol analysis Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study How we treat cytomegalovirus in hematopoietic cell transplant recipients Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation Longterm acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation -a randomized double-blind placebo-controlled study Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease Nosocomial transmission of respiratory syncytial virus in an outpatient cancer center Human rhinovirus RNA detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients Early diagnosis and specific treatment are key factors in reducing the morbidity and mortality of infections in hematology and HCT patients. The rise of multiresistant organ-isms is a major threat and infection control is therefore of uttermost importance.